FI105012B - Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi - Google Patents
Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi Download PDFInfo
- Publication number
- FI105012B FI105012B FI923402A FI923402A FI105012B FI 105012 B FI105012 B FI 105012B FI 923402 A FI923402 A FI 923402A FI 923402 A FI923402 A FI 923402A FI 105012 B FI105012 B FI 105012B
- Authority
- FI
- Finland
- Prior art keywords
- cyclodextrin
- erythropoietin
- epo
- aqueous solution
- hydroxypropyl
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Polyurethanes Or Polyureas (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9001987 | 1990-01-29 | ||
GB909001987A GB9001987D0 (en) | 1990-01-29 | 1990-01-29 | Improved cyclodextrin based erythropietin formulation |
EP9100173 | 1991-01-25 | ||
PCT/EP1991/000173 WO1991011200A1 (fr) | 1990-01-29 | 1991-01-25 | Composition d'erythropoïetine amelioree a base de cyclodextrine |
Publications (3)
Publication Number | Publication Date |
---|---|
FI923402A FI923402A (fi) | 1992-07-28 |
FI923402A0 FI923402A0 (fi) | 1992-07-28 |
FI105012B true FI105012B (fi) | 2000-05-31 |
Family
ID=10670074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI923402A FI105012B (fi) | 1990-01-29 | 1992-07-28 | Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi |
Country Status (20)
Country | Link |
---|---|
US (1) | US5376632A (fr) |
EP (1) | EP0513072B1 (fr) |
JP (1) | JP2997052B2 (fr) |
KR (1) | KR0183445B1 (fr) |
AT (1) | ATE107518T1 (fr) |
AU (1) | AU648061B2 (fr) |
CA (1) | CA2074820C (fr) |
DE (1) | DE69102627T2 (fr) |
DK (1) | DK0513072T3 (fr) |
ES (1) | ES2059115T3 (fr) |
FI (1) | FI105012B (fr) |
GB (1) | GB9001987D0 (fr) |
HU (1) | HU218213B (fr) |
IE (1) | IE65209B1 (fr) |
IL (1) | IL97019A (fr) |
NO (1) | NO304728B1 (fr) |
NZ (1) | NZ236938A (fr) |
PT (1) | PT96593B (fr) |
WO (1) | WO1991011200A1 (fr) |
ZA (1) | ZA91620B (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4126984A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke |
US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
US5494901A (en) * | 1993-01-05 | 1996-02-27 | Javitt; Jonathan C. | Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent |
IL116085A (en) | 1994-12-16 | 1999-12-31 | Ortho Pharma Corp | Spray dried erythropoietin |
DE19539574A1 (de) * | 1995-10-25 | 1997-04-30 | Boehringer Mannheim Gmbh | Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren |
DE69733664T3 (de) | 1996-04-19 | 2011-04-14 | Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles | Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen |
US5754937A (en) | 1996-05-15 | 1998-05-19 | Stackpole Limited | Hi-density forming process |
NZ337465A (en) * | 1997-03-18 | 2002-04-26 | Roche Diagnostics Gmbh | Pharmaceutical containing erythropoietin and iron preparations for treating haemodialysis patients or anaemias |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
US20040152664A1 (en) * | 1998-09-02 | 2004-08-05 | Allergan, Inc. | Prednisolone compositions |
CA2342797A1 (fr) | 1998-09-02 | 2000-03-09 | Allergan Sales, Inc. | Compositions contenant de la cyclodextrine et un agent conservateur |
EP1181036B1 (fr) * | 1999-04-09 | 2008-07-23 | Ortho-Mcneil Pharmaceutical, Inc. | Composition pharmaceutique d'erythropoietine |
EP1336410A4 (fr) * | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | Preparations proteiniques a injecter |
US20060235366A1 (en) * | 2000-12-20 | 2006-10-19 | Fox Hollow Technologies, Inc. | Method of evaluating a treatment for vascular disease |
US20020146409A1 (en) * | 2001-01-30 | 2002-10-10 | Herring Steven W. | Methods for stabilizing lyophilized blood proteins |
EP1413310A1 (fr) * | 2001-07-09 | 2004-04-28 | Yamanouchi Pharmaceutical Co. Ltd. | Compositions a liberation prolongee a injecter et procede de production associe |
DE10228049A1 (de) * | 2002-06-24 | 2004-01-15 | Merck Patent Gmbh | Flüssige Zubereitung enthaltend Oligopeptide |
US7459435B2 (en) * | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US7459436B2 (en) * | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
WO2004108152A1 (fr) * | 2003-06-10 | 2004-12-16 | Lg Life Sciences Ltd. | Solutions aqueuses stables d'erythropoietine humaine ne contenant pas d'albumine serique |
EP1537876A1 (fr) * | 2003-12-01 | 2005-06-08 | BioGeneriX AG | Formulation d'une solution d'érythropoiétine |
US7772182B2 (en) * | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
US20110236902A1 (en) * | 2004-12-13 | 2011-09-29 | Tyco Healthcare Group Lp | Testing a patient population having a cardiovascular condition for drug efficacy |
US7794413B2 (en) * | 2005-04-19 | 2010-09-14 | Ev3, Inc. | Libraries and data structures of materials removed by debulking catheters |
CU23317A1 (es) * | 2005-07-22 | 2008-10-22 | Ct De Investigacia N Y Desarro | Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central |
AU2007325576B2 (en) | 2006-10-20 | 2013-01-10 | Icos Corporation | Compositions of Chk1 inhibitors |
ES2632164T3 (es) * | 2010-07-06 | 2017-09-11 | Augustinus Bader | Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea |
US10328152B2 (en) | 2011-06-16 | 2019-06-25 | Nayan Patel | Method for stabilization and delivery of therapeutic molecules |
US11583584B1 (en) * | 2015-10-28 | 2023-02-21 | Coherus Biosciences, Inc. | Stable protein compositions and methods of their use |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
JPS60258125A (ja) * | 1984-06-06 | 1985-12-20 | Hayashibara Biochem Lab Inc | 蛋白性生理活性物質を含有する水溶性乾燥物 |
JPS6191131A (ja) * | 1984-10-09 | 1986-05-09 | Chugai Pharmaceut Co Ltd | 医薬品の吸着防止方法および組成物 |
JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
US4920214A (en) * | 1986-04-16 | 1990-04-24 | American Maize-Products Company | Process for producing modified cyclodextrins |
PT88490B (pt) * | 1987-09-14 | 1992-11-30 | Novo Nordisk As | Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5068227A (en) * | 1989-01-18 | 1991-11-26 | Cyclex, Inc. | Cyclodextrins as carriers |
-
1990
- 1990-01-29 GB GB909001987A patent/GB9001987D0/en active Pending
-
1991
- 1991-01-24 IL IL97019A patent/IL97019A/xx active IP Right Grant
- 1991-01-25 DE DE69102627T patent/DE69102627T2/de not_active Revoked
- 1991-01-25 AU AU71497/91A patent/AU648061B2/en not_active Ceased
- 1991-01-25 AT AT91902955T patent/ATE107518T1/de not_active IP Right Cessation
- 1991-01-25 JP JP3503095A patent/JP2997052B2/ja not_active Expired - Fee Related
- 1991-01-25 DK DK91902955.3T patent/DK0513072T3/da active
- 1991-01-25 EP EP91902955A patent/EP0513072B1/fr not_active Revoked
- 1991-01-25 HU HU9202432A patent/HU218213B/hu unknown
- 1991-01-25 CA CA002074820A patent/CA2074820C/fr not_active Expired - Fee Related
- 1991-01-25 WO PCT/EP1991/000173 patent/WO1991011200A1/fr not_active Application Discontinuation
- 1991-01-25 ES ES91902955T patent/ES2059115T3/es not_active Expired - Lifetime
- 1991-01-28 ZA ZA91620A patent/ZA91620B/xx unknown
- 1991-01-28 IE IE28691A patent/IE65209B1/en not_active IP Right Cessation
- 1991-01-29 NZ NZ236938A patent/NZ236938A/en unknown
- 1991-01-29 PT PT96593A patent/PT96593B/pt not_active IP Right Cessation
-
1992
- 1992-06-30 US US07/906,780 patent/US5376632A/en not_active Expired - Lifetime
- 1992-07-24 KR KR1019920701755A patent/KR0183445B1/ko not_active IP Right Cessation
- 1992-07-28 FI FI923402A patent/FI105012B/fi not_active IP Right Cessation
- 1992-07-29 NO NO922990A patent/NO304728B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
KR0183445B1 (en) | 1999-05-01 |
NZ236938A (en) | 1992-07-28 |
AU7149791A (en) | 1991-08-21 |
EP0513072A1 (fr) | 1992-11-19 |
NO922990D0 (no) | 1992-07-29 |
ES2059115T3 (es) | 1994-11-01 |
GB9001987D0 (en) | 1990-03-28 |
DE69102627T2 (de) | 1994-11-03 |
IE910286A1 (en) | 1991-07-31 |
DK0513072T3 (da) | 1994-08-01 |
PT96593A (pt) | 1991-10-15 |
IE65209B1 (en) | 1995-10-04 |
IL97019A0 (en) | 1992-03-29 |
WO1991011200A1 (fr) | 1991-08-08 |
HU218213B (hu) | 2000-06-28 |
CA2074820A1 (fr) | 1991-07-30 |
IL97019A (en) | 1997-07-13 |
EP0513072B1 (fr) | 1994-06-22 |
FI923402A (fi) | 1992-07-28 |
HUT62198A (en) | 1993-04-28 |
NO922990L (no) | 1992-07-29 |
NO304728B1 (no) | 1999-02-08 |
ZA91620B (en) | 1992-10-28 |
AU648061B2 (en) | 1994-04-14 |
FI923402A0 (fi) | 1992-07-28 |
DE69102627D1 (de) | 1994-07-28 |
ATE107518T1 (de) | 1994-07-15 |
JPH05503700A (ja) | 1993-06-17 |
JP2997052B2 (ja) | 2000-01-11 |
PT96593B (pt) | 2001-06-29 |
HU9202432D0 (en) | 1992-10-28 |
US5376632A (en) | 1994-12-27 |
CA2074820C (fr) | 2003-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI105012B (fi) | Menetelmä syklodekstriinipohjaisen erytropoietiiniformulaation valmistamiseksi | |
Brewster et al. | Use of 2-hydroxypropyl-β-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs | |
JP6444548B2 (ja) | スルホアルキルエーテルシクロデキストリン組成物 | |
US10323103B2 (en) | Alkylated cyclodextrin compositions and processes for preparing and using the same | |
EP1501496B1 (fr) | Preparations contenant de l'amiodarone et un sulfoalkylether de cyclodextrine | |
US20030055023A1 (en) | Formulations containing etomidate and a sulfoalkyl ether cyclodextrin | |
KR102112119B1 (ko) | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 | |
JP5052750B2 (ja) | オリゴペプチドとエーテル化シクロデキストリンを含む液体製剤 | |
JPH07316065A (ja) | Fr901469物質製剤 | |
US20230357451A1 (en) | Alkylated cyclodextrin compositions and processes for preparing and using the same | |
JPH0129482B2 (fr) | ||
JPS6131121B2 (fr) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MA | Patent expired |